Showing results (1111-1120 of 1,193) with videos related to

Sort By:
Pageof 120
The Australasian Journal of Dermatology|August 6, 2025
Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients-Results From an Australian Expert Consensus ExerciseMeryl Thomas, Madeline Hankins, Emadodin Darchini-Maragheh, et al.
Biorxiv : the Preprint Server for Biology|February 27, 2026
Non-canonical function of the splicing activator U2AF2 in promoting intron retention in the lncRNAs <i>PURPL</i> and <i>MALAT1</i>Ioannis Grammatikakis, Chosita Norkaew, You Jin Song, et al.
Science Translational Medicine|September 5, 2014
The HMGB1-RAGE axis mediates traumatic brain injury-induced pulmonary dysfunction in lung transplantationDaniel J Weber, Adam S A Gracon, Matthew S Ripsch, et al.
BMC Cancer|August 30, 2019
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapyMehmet Asim Bilen, Julie M Shabto, Dylan J Martini, et al.
The Journal of Biological Chemistry|May 5, 2017
HMG-CoA synthase 1 is a synthetic lethal partner of BRAF<sup>V600E</sup> in human cancersLiang Zhao, Jun Fan, Siyuan Xia, et al.
Brainlesion : Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries. Brainles (Workshop)|August 6, 2020
The Cancer Imaging Phenomics Toolkit (CaPTk): Technical OverviewSarthak Pati, Ashish Singh, Saima Rathore, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 18, 2013
Role of complement activation in obliterative bronchiolitis post-lung transplantationHidemi Suzuki, Mark E Lasbury, Lin Fan, et al.
Journal of Medical Imaging (Bellingham, Wash.)|January 18, 2018
Cancer imaging phenomics toolkit: quantitative imaging analytics for precision diagnostics and predictive modeling of clinical outcomeChristos Davatzikos, Saima Rathore, Spyridon Bakas, et al.
The Lancet. Oncology|May 19, 2015
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trialMichael R Migden, Alexander Guminski, Ralf Gutzmer, et al.
Journal of the American Academy of Dermatology|April 13, 2016
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinomaReinhard Dummer, Alexander Guminski, Ralf Gutzmer, et al.
Pageof 120